Press Release Tuesday 5th June 2018
The information contained within this announcement is deemed by the Company to constitute inside information stipulated under the Market Abuse Regulation (EU) No. 596/2014. Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.
Sativa Investments PLC
(“Sativa” or “the Company”)
Sativa seeks to broaden investment policy to meet
widening global demand for medicinal cannabis.
General Meeting on 22 June 2018 to amend existing investment policy.
Sativa Investments PLC (NEX:SATI), the UK’s first medicinal cannabis investment vehicle, is seeking shareholder approval to broaden its investment policy beyond Canada and has today notified shareholders of a General Meeting to be held on 22 June 2018, in order to seek their approval. The Company is also seeking shareholder approval relating to authority to allot shares and also relating to the disapplication of pre-emption rights. A copy of the Circular, which was posted today, is available on the Company’s website www.sativainvestments.com
Since listing on the NEX Exchange Growth Market on Thursday 29th March 2018, Sativa has pursued numerous potential investments and has already announced two investments, these being in Veritas Pharma Inc. and Rapid Dose Therapeutics Inc. on 21 May and 23 May respectively.
Geremy Thomas, founder and Chief Executive Officer of Sativa, said: “Even since Sativa’s IPO in March this year, the global interest in medicinal cannabis has grown considerably. The increased political attention to generic access to what are established and legal therapies in many jurisdictions means that the opportunity to build shareholder value goes far beyond medicinal cannabis ventures in Canada alone.
“The UK is seeing an increasing debate over access to medicinal cannabis and legislatory change here is a realistic possibility, with the Legalisation of Cannabis (Medicinal Purposes) Bill 2017-19 expected to have its second reading debate in Parliament on Friday 6 July 2018, a scenario which is likely to be mirrored across Europe. Sativa is well placed to participate in meeting any future European or wider global demand whilst continuing to invest in the well- established Canadian market.”
The Directors of the Company accept responsibility for the contents of this announcement.
– Ends –
For further information please contact:
Founder & Chief Executive Officer
Sativa Investments PLC
+44 (0) 20 7971 1255
NEX Exchange Corporate Adviser
Peterhouse Corporate Finance Limited
+44 (0) 20 7469 0930
Financial PR and IR
Julian Bosdet / Dylan Mark /Alejandra Campuzano
+44 (0) 20 7469 4630
Notes to Editors
Sativa will look for well-placed opportunities within the dynamic regulatory environment of the Medicinal Cannabis sector and the Company’s investment strategy will focus on the production, testing and compliance, research and development, including pharmacology, commercialisation and sales and marketing of Medicinal Cannabis in jurisdictions where it is regulatorily accepted, with an initial focus on Canada. The Company has committed to an independent legal review prior to each investment to verify compliance with the prevailing regulatory environment.
The Company’s equity interest in a proposed investment may range from a minority position, to a controlling interest, or to 100 per cent ownership. The ventures that Sativa intends to acquire can either be public or private.
The Company’s Board and Medical Cannabis Advisory Board have a combined 60 years’industry experience with strong and extensive contacts in the industry, with significant pharmaceutical strength and experience. Their extensive skills range from capital fund raisings, medical research, and start-ups, to pharmaceutical development.
For more information on Sativa Investments, please visit: https://sativainvestments.co.uk/